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Discussion
Dr Walter Weder (Zurich, Switzerland). I would like to
congratulate Dr Ali and the group from Boston for their clinically
relevant contribution to surgical treatment of local recurrences by
chest wall resection in patients with malignant pleural mesotheli-
oma. I received the report in time for a critical review.
Dr Ali and colleagues identified 47 patients with local recur-
rence of malignant pleural mesothelioma who were amenable
for resection of 1142 patients who had undergone radical resection
either by EPP (794 patients) or PD (348 patients). This accounts
for 4.1% of all operated cases. Taking into consideration that the
reported local recurrence rate in the ipsilateral chest after EPP is
around 35% to 40% and probably even higher after PD, only
around 12% of all patients with local recurrence were selected
for surgical treatment. In part, this relatively small number
was because patient follow-up was done outside your service.
Nevertheless, it seems that you have been very selective.
This brings me to my first question. How did you exactly select
your patients? Was it based primarily on CT scan, looking for a
localized resectable bulk, or was the clinical picture more
important—nonfixed tumor, pain? Is there an upper tumor size
or tumor extension? How important are the positron emission
tomography findings, which clearly show local extension more
precisely? Does it matter if the planned resection will be radical
or not? Is patient selection for chest wall resection different for
patients after EPP than after PD?
Dr Ali. The way we select our patients is we follow them up in
our postoperative clinic and we obtain routine CT scans. The first
CT scan is done at 6 to 8 weeks and serves as a baseline. There-
after, we repeat the CT scans every 4 months. Usually on imaging
or on the clinical examination, if there is a suspicion of recurrent
disease, we often obtain a positron emission tomography-CT
scan. This is how we identify recurrent disease.
As far as who is a good candidate for chest wall resection, this is
basically solitary or isolated disease. As we saw in this breakdown,The Journal of Thoracic and Carabout one half of them were at the incisional site, and 38% were at
the costophrenic angle. As you can imagine, the incisional site is
most likely because of tumor seeding, and perhaps the disease at
the costophrenic angle was secondary to this being a difficult
area to achieve macroscopic clearance at. The patients are selected
primarily on the criteria based on the question, ‘‘Can we achieve
complete resection and return them to their decreased tumor
burden?’’ It is like resetting the tumor burden. If we believe the
patient has more than 1 thoracic recurrence (ie, it is not solitary
disease), we would offer them surgery. However, this study
included only patients with solitary recurrent disease. If
extrathoracic diseases present, as well as chest wall recurrence,
generally speaking, they would not be offered chest wall resection.
As to your last point, the extent of resection, for patients
who had disease in the costophrenic sulcus, often it extends
contiguously into the retroperitoneum, and we had at least
3 patients in this study who ended up undergoing an en bloc
retroperitoneal mass resection. In 2 patients, the disease extended
toward the mediastinum, and the remnant diaphragmatic crura was
resected en bloc with the chest wall resection.
Dr Weder. In your study, you showed nicely that early recur-
rence is a poor prognostic sign, an observation also made in other
clinical questions with malignancies, such as surgical treatment of
metastasis. My second question regards the indication for surgery
in relation to the onset of the recurrence. In which cases do you not
recommend surgery because of the expected aggressive biologic
behavior of the tumor? Is there a recommended cutoff time?
Dr Ali. That is a very good question. As you know, in
mesothelioma, the primary determinant of survival is the cell
type, or, in other words, the tumor biology. The epithelial cell
type tends to have a longer survival. In this study, patients who
had their first recurrence after primary macroscopic resection,
when the TTR (or time to recurrence) was more than 24 months,
their median survival was 35.9 months. Now, in the same study,
we had patients with biphasic-type disease whose TTR was less
than 10 months, and their median survival after chest wall
resection was a mere 2.7 months. So clearly, the tumor biology
is an important determinant. I think this allows us to determine
the criteria according to the TTR as to which patients we should
offer a second surgery to.
Dr Shrager. I think his question was what criteria would you
propose.
Dr Ali. I think for the biphasic type, when they recur early,
you have to consider other therapies, such as radiotherapy or
second-line, third-line chemotherapy, especially when they recur
within less than 10 months. Now, this study has 47 patients who
were highly selected. So I think we can use this as a guideline in
the future, especially for the biphasic type.
Dr Weder. But those with the epithelial type, those with early
recurrence had a very poor prognosis. So, I would not make the
cutoff exactly just for the mixed type. I think also the epithelial
type can behave very aggressively when it occurs early. So my
last question is, what about local recurrence after chest wall
resection, especially in these aggressive subtypes, did you see
problems in this regard?
Dr Ali. Yes. One third of these patients ended up undergoing a
second chest wall resection. We believe if there is repeat
recurrence and if we can resect it and return the patients back todiovascular Surgery c Volume 146, Number 6 1379
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Stheir previous tumor burden, that is, reset their homeostasis, so to
speak, then we would offer them surgery. The median survival for
patients who had undergone 2 or more resections was actually 59
months. So, in a way, in this highly selected subset of patients,
repeat recurrence was not an impediment to repeat resection.
Dr Weder. Also, for the one who had occurred early, the very
aggressive one, you have not seen recurrence there?
Dr Ali. No. Those who recurred early, no, we did not.
Dr Weder. Thank you very much.
Dr Robert B. Cameron (Los Angeles, Calif). I want to
congratulate you on an obviously impressive series. I have a lot
of questions, but I will limit them to 2.
First is regarding the 25-year period that you are reporting on.
I am just curious, because a number of other things have
been developed during that 25 years, including stereotactic
body radiotherapy, radiofrequency ablation, and other localized
treatments that are short of surgery. Can you comment on the
use of those in your series? Did you use any of them, and did
you find that they were less effective? Also, in light of that, does
any difference exist in morbidity in performing chest wall
resection vs performing stereotactic body radiotherapy?
Dr Ali. That is a very good question. These are cases from our
database, and the selection criterion was to include patients who
had undergone chest wall resection for solitary disease. So in this
study, we could not compare other modalities based on that. Having
said that, for recurrent disease at the costophrenic sulcus, for
example, radiotherapy often has its limits of how much radiation
you can give. There are radiosensitive organs at the costophrenic
sulcus such as the stomach on the left and liver on the right, and, sec-
ond, often patients have reached theirmaximum radiation limit after
multimodality therapy for mesothelioma. In patients who have un-
dergone PDwith their lung still in the ipsilateral chest, radiotherapy
can be associated with side effects such as radiation pneumonitis.
So, clearly, there are certain side limitations one must keep in
mind. I cannot comment on which technique is superior.1380 The Journal of Thoracic and Cardiovascular SurDr Cameron. I would like to take the opportunity, then, to
invite you to the ethereal world of the ‘‘POD.’’We have an abstract
that is in the POD downstairs, wherever that is, that reports on 86
lesions that were treated with cryoablation of local recurrence after
pleurectomy, and we had a success rate of permanent control of
those lesions 98% of the time without any surgery. So, I would
just invite you to review that because I think that that will basically
obviate the need for any chest wall resection, and a lot of those
were chest wall recurrences that were treated successfully up to
6 cm.
I have to ask 1 last question, which is kind of the elephant in the
room. Whenever you talk about mesothelioma, everybody says,
well, we have no randomized trials and all that sort of thing, but
you just reported on almost 800 EPPs.With the mounting evidence
from a number of different groups, including the Mesothelioma
and Radical Surgery (MARS) trial, that EPP might not have any
benefit in this disease, are we going to be hearing in the near future
about your randomized prospective clinical trial of EPP and
whether it works or not?
Dr Ali. I think in surgery for mesothelioma, there could be
some debate, but clearly the results from our institution show
that excellent survival can achieved using a multimodality,
surgery-based approach, and I think what we are showing here
today is that a second surgery for select cases should also be
considered.
Dr Antoon Lerut (Leuven, Belgium). Thank you for an
excellent presentation.
I would like to come back to the 1 of 3 patients who underwent a
second chest wall resection. You mentioned that the overall
median survival was 59 months from the date of primary surgery,
but what was the median survival from the date of the second
chest wall resection? That perhaps might give an idea about the
aggressiveness of the second recurrence.
Dr Ali. In those 16 patients, their median survival after the
second resection was 14.5 months.gery c December 2013
